Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Pevonedistat (Primary) ; Docetaxel
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 29 Jan 2018 Status changed from not yet recruiting to recruiting.
- 08 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
- 13 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.